Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 9/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.35 |
| ▸ | APBA1 | Q02410 | 2/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | CCR6 | P51684 | 1/20 | 0.34 |
| ▸ | CDK1 | P06493 | 1/20 | 0.34 |
| ▸ | TACR1 | P25103 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | ALPL | P05186 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8706759 | 0.81 | NOTUM (0.40) | NOTUMALDH1A1MAPTHPGDHTT | |
| SCHEMBL310305 | 0.81 | TACR1 (0.44) | ALDH1A1MAPTHPGDTACR1KDM4E | |
| SCHEMBL5820443 | 0.81 | TACR1 (0.36) | NOTUMALDH1A1MAPTHPGDHTT | |
| SCHEMBL7193387 | 0.79 | TACR1 (0.41) | TACR1 | |
| SCHEMBL3814197 | 0.79 | LMNA (0.47) | ERN1NOTUMCDK1LMNAALPL | |
| SCHEMBL3821496 | 0.79 | TACR1 (0.37) | TACR1 | |
| SCHEMBL7495021 | 0.79 | ALDH1A1 (0.31) | ALDH1A1MAPTHPGDHTTCACNA1B | |
| SCHEMBL8706262 | 0.78 | TACR1 (0.37) | NOTUMALDH1A1MAPTHPGDHTT | |
| SCHEMBL4203119 | 0.78 | TACR1 (0.43) | TACR1LMNA | |
| SCHEMBL7193383 | 0.78 | TACR1 (0.40) | TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093268-B2 | Pharmaceutical compositions comprising 2-methoxy-5-(5-trifluoromethyl-tetrazol-1-yl-benzyl)-(2S-phenylpiperidin-3S-yl-) | GLAXO GROUP LIMITED (GB) | 2012-01-10 | — | — | US | disclosed |
| EP-2117535-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NK1 RECEPTOR ANTAGONISTS AND SODIUM CHANNEL BLOCKERS | GLAXO GROUP LTD (GB) | 2011-10-26 | — | — | EP | disclosed |
| EP-2117562-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NK1 RECEPTOR ANTAGONISTS AND SODIUM CHANNEL BLOCKERS | GLAXO GROUP LTD (GB) | 2011-10-26 | — | — | EP | disclosed |
| CN-101959513-A | Novel pharmaceutical composition | GLAXO GROUP LTD | 2011-01-26 | — | — | CN | disclosed |
| US-20100113521-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 2-METHOXY-5-(5-TRIFLUOROMETHYL-TETRAZOL-1-YL-BENZYL)-(2S-PHENYLPIPERIDIN-3S-YL-) | GLAXO GROUP LIMITED (GB) | 2010-05-06 | — | — | US | disclosed |
| US-20100105688-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 3,5-DIAMINO-6-(2,3-DICHLOPHENYL)-1,2,4-TRIAZINE OR R(-)-2,4-DIAMINO-5-(2,3-DICHLOROPHENYL)-6-FLUOROMETHYL PYRIMIDINE AND AN NK1 | GLAXO GROUP LIMITED (GB) | 2010-04-29 | — | — | US | disclosed |
| CN-101641102-A | Pharmaceutical compositions comprising NK1 receptor antagonists and sodium channel blockers | GLAXO GROUP LTD GB | 2010-02-03 | — | — | CN | disclosed |
| CN-101641099-A | Pharmaceutical composition comprising 3, 5-diamino-6- (2, 3-dichlorophenyl) -1, 2, 4-triazine or R (-) -2, 4-diamino-5- (2, 3-dichlorophenyl) -6-fluoromethylpyrimidine and NK1 | GLAXO GROUP LTD GB | 2010-02-03 | — | — | CN | disclosed |
| US-20090326032-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NK1 RECEPTOR ANTAGONISTS AND SODIUM CHANNEL BLOCKERS | GLAXO GROUP LIMITED (GB) | 2009-12-31 | — | — | US | disclosed |
| US-20090318530-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NK1 RECEPTOR ANTAGONISTS AND SODIUM CHANNEL BLOCKERS | GLAXO GROUP LIMITED (GB) | 2009-12-24 | — | — | US | disclosed |
| US-5919803-A | TACHYKININ ANTAGONIST | GLAXO GROUP LIMITED (GB) | 1999-07-06 | — | — | US | disclosed |
| US-5843966-A | Piperidine derivatives | GLAXO GROUP LIMITED (GB) | 1998-12-01 | — | — | US | disclosed |
| EP-0720609-B1 | 3-(5-TETRAZOLYL-BENZYL)AMINO-PIPERIDINE DERIVATIVES AND ANTAGONISTS OF TACHYKININS | GLAXO GROUP LTD (GB) | 1998-11-11 | — | — | EP | disclosed |
| EP-0815104-A1 | 3-BENZYLAMINO-2-PHENYLPIPERIDINES AS NEUROKININ ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 1998-01-07 | — | — | EP | disclosed |
| US-5703240-A | ANALGESICS; ANTIINFLAMMATORY AGENTS; NERVOUS SYSTEM DISORDERS; PSYCHOLOGICAL DISORDERS; GASTROINTESTINAL DISORDERS | GLAXO GROUP LIMITED (GB) | 1997-12-30 | — | — | US | disclosed |
| EP-0802912-A1 | PIPERIDINE DERIVATIVES HAVING TACHYKININ ANTAGONIST ACTIVITY | GLAXO GROUP LIMITED (GB) | 1997-10-29 | — | — | EP | disclosed |
| WO-1996029326-A1 | 3-BENZYLAMINO-2-PHENYLPIPERIDINES AS NEUROKININ ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 1996-09-26 | — | — | WO | disclosed |
| WO-1996021661-A1 | PIPERIDINE DERIVATIVES HAVING TACHYKININ ANTAGONIST ACTIVITY | GLAXO GROUP LIMITED (GB) | 1996-07-18 | — | — | WO | disclosed |
| EP-0720609-A1 | 3-(5-TETRAZOLYL-BENZYL)AMINO-PIPERIDINE DERIVATIVES AND ANTAGONISTS OF TACHYKININS | GLAXO GROUP LIMITED (GB) | 1996-07-10 | — | — | EP | disclosed |
| WO-1995008549-A1 | 3-(5-TETRAZOLYL-BENZYL)AMINO-PIPERIDINE DERIVATIVES AND ANTAGONISTS OF TACHYKININS | GLAXO GROUP LIMITED (GB) | 1995-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318530-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NK1 RECEPTOR ANTAGONISTS AND SODIUM CHANNEL BLOCKERS | HCRTR1, TACR2, CNR1 | ERN1 1700/4885NOTUM 3661/4885ALDH1A1 1556/4885 |
| US-20100105688-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 3,5-DIAMINO-6-(2,3-DICHLOPHENYL)-1,2,4-TRIAZINE OR R(-)-2,4-DIAMINO-5-(2,3-DICHLOROPHENYL)-6-FLUOROMETHYL PYRIMIDINE AND AN NK1 | KCNJ2, SCN5A, GRIK5 | ERN1 3107/4885NOTUM 3664/4885ALDH1A1 1449/4885 |
| US-20100113521-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 2-METHOXY-5-(5-TRIFLUOROMETHYL-TETRAZOL-1-YL-BENZYL)-(2S-PHENYLPIPERIDIN-3S-YL-) | KCNJ2, TRPV1, SCN5A | ERN1 3672/4885NOTUM 3596/4885ALDH1A1 2016/4885 |
| US-20090326032-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NK1 RECEPTOR ANTAGONISTS AND SODIUM CHANNEL BLOCKERS | TACR2, TACR1, KCNH3 | ERN1 2188/4885NOTUM 3739/4885ALDH1A1 1391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.